

Germline pathogenic variants in 786 neuroblastoma patients

SUPPLEMENTARY INFORMATION

Table of Contents

I. SUPPLEMENTARY METHODS	2
II. SUPPLEMENTARY TABLES	8
eTable 1. Neuroblastoma patient clinical, tumor biologic and sequencing data (Excel file).....	8
eTable 2. Cancer predisposition genes panel (n=166) used in study (Excel File)	8
eTable 3. Cancer predisposition gene P-LP variants observed in neuroblastoma (Excel File)	8
eTable 4. Neuroblastoma cases harboring multiple germline P-LP variants in CPGs.....	9
eTable 5. Primers for Sanger sequencing validation germline variants	10
eTable 6. Gene-based testing for excess burden of P-LP variants vs. PMBB (Excel File).....	11
eTable 7. Gene-based testing for excess burden of P-LP variants vs. gnomAD 2.1 (Excel File)	11
eTable 8. P-LP variants in genes with excess burden in neuroblastoma.....	12
eTable 9. Rare germline copy number variants (CNVs) disrupting <i>BARD1</i> in neuroblastoma cases.....	13
eTable 10. Association of P-LP variants with clinical and tumor characteristics (Full Cohort).....	14
eTable 11. Association of P-LP variants with clinical and tumor characteristics (Capture Only)	15
eTable 12. Cox proportional hazards regression model results.	16
III. SUPPLEMENTARY FIGURES	17
eFigure 1. Flow diagram of automated pathogenicity assessment for germline variants.	17
Order of flow indicated by labeled arrows.....	17
eFigure 2. Ancestry of neuroblastoma cohort inferred from principal component analysis.	18
eFigure 3. <i>BARD1</i> germline variants validated by Sanger sequencing.	19
eFigure 4. <i>EZH2</i> P/LP germline and somatic variants validated by Sanger sequencing.	20
eFigure 5. Ancestry of PMBB cohort inferred from principal component analysis.	21
IV. BANNER AUTHOR LISTS AND CONTRIBUTIONS	22
Penn Medicine BioBank Banner Author List and Contribution Statements.....	22
Regeneron Genetics Center Banner Author List and Contribution Statements.....	23
V. SUPPLEMENTARY REFERENCES	24

I. SUPPLEMENTARY METHODS

Neuroblastoma patient samples

A total of 786 neuroblastoma patients accrued through the North American-based Children's Oncology Group (COG) ANBL00B1 biology study were included in the study (**Table 1, eTable 1**). Patients were unselected for family history of neuroblastoma. Genomic DNA was extracted from peripheral blood lymphocyte samples and obtained through the COG nucleic acids bank housed at the Children's Hospital of Philadelphia (CHOP). Matched diagnostic tumor DNA and RNA was also obtained from the same biobank. The patient cohort was intentionally enriched for high-risk disease and poor outcome through the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative. We have previously reported a small number of germline variants based on exome sequencing in a subset (n=222) of these patients¹; however, an in-depth study of pathogenic germline variation in these children was not performed at that time.

Penn Med Biobank (PMBB)

The Penn Medicine BioBank (PMBB) is a precision medicine cohort with genomic profiling of participants who consented for biospecimen collection and linkage of their biospecimen to their electronic health record (EHR) data.² Starting in 2004, participants were recruited into PMBB at the time of medical appointments in the University of Pennsylvania Health System. All individuals recruited were patients of clinical practice sites of the University of Pennsylvania Health System. Appropriate consent was obtained from each participant regarding storage of biological specimens, genetic sequencing, access to all available EHR data, and permission to recontact for future studies. The study was approved by the Institutional Review Board of the University of Pennsylvania.

Phenotyping and identification of PMBB participants who were cancer-free and also had no history of a benign tumor was performed as described previously.³ Briefly, participants with cancer were identified from the EHR using International Classification of Diseases (ICD)-9 or ICD-10 billing codes. These included both prevalent and

incident cases. We then defined a cancer- and tumor-free control cohort as individuals with no ICD-9/10 codes for invasive cancer, benign, in situ, or secondary neoplasms (n=6,295).

In this study, we included 6,295 individuals who had undergone whole-exome sequencing (WES) and germline genome-wide DNA array-based genotyping. For each individual, DNA was extracted from stored buffy coats and then exome sequences were generated by the Regeneron Genetics Center (Tarrytown, NY) and obtained for study. For purposes of this study, all WES data were reprocessed as described above for neuroblastoma data. Germline genome-wide DNA array-based genotyping using the Infinium Global Screening Array (GSA) chip (Illumina) was utilized to infer ancestry of the 6,295 individuals in the cancer- and tumor-free control cohort. Genotyping was performed at the Children's Hospital of Philadelphia or Regeneron Genetics Center as previously described.³

Ancestry inference

Paired germline single nucleotide polymorphism (SNP) array data were utilized to infer ancestry of neuroblastoma and Penn Medicine Biobank (PMBB) control subjects. Genotypes from neuroblastoma cases were intersected with data from the International HapMap Project (HapMap v3, draft release 2). The variants were pruned using a window size of 50 variants, step size of five variants, and pairwise r^2 threshold of 0.2. A principal component analysis (PCA) was performed using PLINK 1.9 and ancestry inferred as previously described⁴. SNP array data from PMBB samples were processed in an identical manner. Neuroblastoma SNP array data are available through the Database of Genotypes and Phenotypes (dbGaP), accession phs000124.v3.p1.

Genomic sequencing

Genomic DNA was sequenced using a combination of Complete Genomics whole genome sequencing (WGS), Illumina whole exome sequencing (WES), and Illumina targeted capture sequencing (CAP). Complete Genomics WGS (n=134) and Illumina WES (n=222) of matched tumor-normal DNA pairs was generated through the TARGET initiative (<https://ocg.cancer.gov/programs/target/data-matrix>), as previously described^{1,5}. A total of 76

tumor-normal pairs were profiled by both WES and WGS, allowing for internal validation (**eTable 1**). An independent set of tumor-normal pairs (n=499) were sequenced by Illumina-based targeted capture sequencing within the TARGET project. Since this TARGET capture panel was designed to include genes known to be somatically mutated in childhood cancer, we constructed a new custom capture panel to include known cancer predisposition genes, neuroblastoma syndrome-related genes, and candidate susceptibility genes identified by GWAS (n=166 genes; **eTable 2**). We performed CAP germline-only sequencing of 489 of the 499 neuroblastoma cases with DNA available. For this CAP sequencing, 200 ng genomic DNA from peripheral blood lymphocyte samples was purified using Agencourt AMPure XP Reagent (Beckman Coulter Inc, Brea, CA, USA) and a next-generation sequencing library was prepared with the KAPA HyperPlus Kit (KAPA Biosystems, Wilmington, MA) using Bioo Scientific NEXTflex™ DNA Barcoded Adapters (Bioo Scientific, Austin, TX, USA) according to KAPA-provided protocol. Libraries were barcoded, amplified, pooled, and captured using NimbleGen's SeqCap EZ Choice Library with custom-designed 523-gene panel (Roche NimbleGen, Inc., Madison, WI, USA). Captured pooled libraries were amplified, cleaned, quantified, and sequenced on a HiSeq2000 using 2x125 bp paired-end sequencing protocols (Illumina, San Diego, CA, USA). Average depth of coverage for targeted capture regions across all subjects was 198x. Concordance with TARGET CAP germline sequencing was assessed for genes that overlapped in the custom captures.

Germline variant calling and annotation

Variants for Complete Genomics WGS data were produced from Complete Genomics pipeline (v2) in hg19 and single nucleotide variants (SNVs) were filtered as previously described⁶. A decision tree classifier was designed and implemented to retain high-confidence small insertion and deletion (indel) calls from this pipeline. Illumina WES (neuroblastoma and PMBB controls) and CAP (neuroblastoma) data were aligned to hg19 using Burrows Wheeler Aligner (BWA)⁷ v0.7.17. Duplicates were removed using Picard v2.18.17 (<http://broadinstitute.github.io/picard/>) and base quality was adjusted with GATK v 4.1.6. SNVs and indels were called using HaplotypeCaller in GATK and variant quality control filtering was applied as per Broad Institute standard best practices. Resulting variants were annotated using SnpEff⁸ (v4.3t) and ANNOVAR⁹ (2019Oct24).

Germline variants in 166 cancer predisposition genes present on all sequencing platforms were further analyzed. Variants with read-depth coverage ≥ 15 , variant allele fraction ≥ 0.20 , and observed in $< 0.1\%$ across each population in the public control databases non-TCGA ExAC (exonic) or gnomAD v2.1 (non-exonic, splicing) were included in the study.

Assessment of variant pathogenicity

Pathogenicity of retained variants was assessed *in silico* using custom software to evaluate ClinVar (11-25-2020) and a modified execution of InterVar (11-25-2020) (eFigure 1). First, ClinVar calls were considered in a hierarchical manner: (1) expert panel decision, (2) consensus of “badged labs”, when available. Badged labs were defined as clinical laboratories meeting minimum requirements for data sharing to support quality assurance, as defined by ClinGen (<https://www.clinicalgenome.org/tools/clinical-lab-data-sharing-list/> downloaded 12-2020). Next, prior to running InterVar, we adjusted PP5 based on this modified ClinVar assessment and corrected PVS1 using AutoPVS1¹⁰. Variants were then assigned to be pathogenic (P), likely pathogenic (LP), benign (B), likely benign (LB) or variants of unknown significance (VUS) by first considering the adjusted ClinVar results and then the modified InterVar output. This approach was applied to both neuroblastoma cases and controls without cancer samples (PMBB and gnomAD 2.1).

Sanger sequencing

To verify germline variants, primers were designed with Primer3 and PCR reactions were carried out on 25 ng of DNA using optimized conditions for each reaction. Products were checked via gel electrophoresis. If the product had multiple bands, the entire remaining sample was run out then bands of interest excised and the DNA extracted using MinElute Gel Extraction Kit from Qiagen. Products with single bands were cleaned up and prepared for sequencing using the MinElute PCR Purification Kit (Qiagen). Samples were sequenced with two picomoles of the same primer used to create the amplicon.

Germline copy number variant (CNV) analyses

Rare germline CNVs affecting *BARD1* were identified using a SNP genotyping dataset of 5,585 neuroblastoma patients and 23,505 cancer-free control children as previously described¹¹. Briefly, patients diagnosed with neuroblastoma or ganglioneuroblastoma were recruited through the Children's Oncology Group (COG) ANBL00B1 biology study without selection for clinical presentation. Germline DNA was isolated from peripheral blood or bone marrow mononuclear cells at time of diagnosis. Control children were recruited through the Children's Hospital of Philadelphia (CHOP) and screened for cancer and severe neurological or immunological disorders. Cases and controls were genotyped at the CHOP Center for Applied Genomics on matched Illumina SNP arrays and filtered for cryptic relatedness. CNVs were called using Nexus Copy Number 8.0 with linear correction for GC content, requiring a minimum of 10 probes per CNV. B-Allele Frequency (BAF) and Log R Ratio (LRR) plots were visually inspected to rule out potential artifacts.

Somatic variant analyses

Subjects harboring a germline P-LP variant in a cancer-predisposition gene were further assessed using matched tumor sequencing data when available. Specifically, somatic variants previously reported by Brady and colleagues¹² and additional variants from CAP sequencing data generated through TARGET were interrogated to assess potential second hits involving somatic SNVs, translocations, and focal copy number variations. For the TARGET CAP data, 499 tumor-normal pairs were analyzed. Somatic SNV calling was performed using Mutect 1.1.4 and annotated using Variant Effect Predictor (VEP). Somatic copy number variant (CNV) calling was performed using an in-house tool called VisCap, (<https://github.com/pughlab/VisCapCancer>). Tumor and normal bam files were first run through depth of coverage tool by GATK v3.0.0 and depth of coverage output was used as input for the VisCap somatic copy number calling. The calls for CNV were categorized into focal, subgenomic and broad. A focal copy number variation is a case where the whole gene has gone through a copy number change. A subgenomic change is when a few exons of the genes has copy number change and a broad change is for multiple genes undergoing copy number change. As not all of CPGs were included in somatic CAP sequencing for TARGET, we evaluated tumor DNA sequencing from a total of 79 subjects with germline P-LP

variant in CPGs (20 cases with capture sequencing and all (n=59) cases with WES and/or WGS tumor data) were assessed for single nucleotide variation. However, all cases with germline P-LP variants in CPGs were included in tumor DNA copy number analyses.

Statistical analyses

The prevalence of P-LP germline variants in cancer predisposition genes was reported for the neuroblastoma cohort as a whole and within clinical and biological subsets. Fisher's exact test was used to compare clinical characteristics of patients with and without P-LP germline variants in the genes studied. A two-sided Fisher's exact test (p-value < 0.05) was considered significant. Enrichment testing of P-LP variants in cases vs. controls was performed at the overall, gene, and pathway level using Fisher's exact and corresponding odds ratios (ORs) and 95% confidence intervals were computed. Where zeros cause problems with computation of the odds ratio or its confidence intervals, the Woolf logit approach was utilized. A Bonferroni correction was applied to account for multiple testing at the gene level. Kaplan-Meier analyses of event-free and overall survival were performed to compare outcomes of patients with and without germline P-LP variants. A log-rank p-value < 0.05 was considered to be statistically significant. Statistical analyses were performed using R, version 3.3.2 with R Studio, version 1.0.136. Multivariate analyses were performed with a Cox proportional-hazards regression model to identify variables that were independently predictive of outcome. A p-value < 0.05 was considered to indicate statistical significance. Variables considered included: presence of germline P-LP variant, age at diagnosis, INSS stage, *MYCN* amplification status, and risk group. The patient cohort analyzed (n=774) included all those for whom complete data were available for the variables in the model.

II. SUPPLEMENTARY TABLES

eTable 1. Neuroblastoma patient clinical, tumor biologic and sequencing data (Excel file)

This gene panel was designed to capture known cancer predisposition genes (CPGs), genes implicated in neuroblastoma-associated syndromes (syndrome), genes identified through the neuroblastoma genome-wide association study (WGS). CPG: Cancer Predisposition Gene. Chromosome location: hg19.

eTable 2. Cancer predisposition genes panel (n=166) used in study (Excel File)

This gene panel was designed to capture known cancer predisposition genes (CPGs), genes implicated in neuroblastoma-associated syndromes (syndrome), genes identified through the neuroblastoma genome-wide association study (WGS). CPG: Cancer Predisposition Gene. Chromosome location: hg19.

eTable 3. Cancer predisposition gene P-LP variants observed in neuroblastoma (Excel File)

eTable 4. Neuroblastoma cases harboring multiple germline P-LP variants in CPGs

Subject Identifier	COG Risk Group	MYCN status	Sex	Gene	Variant	Pathogenicity
PAPRXW	High	Amplified	Male	<i>ERCC2</i> <i>FANCA</i> <i>GJB2</i>	NM_000400:c.C2150G:p.A717G NM_001286167:c.189+1G>T NM_004004:c.G416A:p.S139N	P: ClinVar P: InterVar P: ClinVar
PARSEA	High	Not Amplified	Male	<i>BARD1</i> <i>ERCC5</i>	NM_000465:c.C448T:p.R150X NM_000123:c.2604_2605del:p.T868fs	P: ClinVar LP: InterVar
PASNEF	High	Not Amplified	Female	<i>BRCA1</i> <i>BRCA2</i>	NM_007297:c.G5101T:p.G1701C NM_000059:c.G3922T:p.E1308X	LP: ClinVar P: ClinVar
PATPXJ	High	Not Amplified	Female	<i>DOCK8</i> <i>GBA</i>	NM_001190458:c.3654delC:p.D1218fs NM_001005741: c.-50G>C	LP: InterVar P: InterVar
PATVTL	High	Amplified	Male	<i>BRCA2</i> <i>MSH3</i>	NM_000059:c.5067dupA:p.A1689fs NM_002439:c.2759delC:p.S920fs	P: ClinVar P: ClinVar
PAUICI	High	Not Amplified	Female	<i>IKZF1</i> <i>PHOX2B</i>	NM_001291845:c.T479A:p.L160X NM_003924:exon3:c.430-2A>G	LP: InterVar P: InterVar

eTable 5. Primers for Sanger sequencing validation germline variants

Gene	Subject	Location (hg19)	Type	Ref	Alt	Forward Primer	Reverse Primer
<i>ATM</i>	PARNCW	11:108165753	missense	G	T	CATTGTAGGGTTTGCAGTGG	TGGCAGAGGATGAATAAACAGG
<i>BARD1</i>	PATGWT	2:215595215	stop gain	C	T	TCCTGGCTTAGGTTTTTCAGA	GCAATGTTCAAGATGCCAAA
<i>BARD1</i>	PASFDU	2:215610566	stop gain	G	T	GATGCCCTGGGTATAGAGAGC	TCTACCCACCTCCCAAATTC
<i>BARD1</i>	PATHJZ	2:215645738	frameshift	T	---	GAGGGCTAAAAGGCTTCTGC	TTTCTGAGGGCACCGTTTGC
<i>BARD1</i>	PARSEA	2:215646150	stop gain	C	T	AAATTCTTCGGGAGCTCCATGTG	TCAGAAACATCTGCAGGAGGAC
<i>BARD1</i>	PAHYWC	2:215657051	stop gain	C	T	AAGTGACTGCATTGGAAGTGG	ATTCCAGAAGTCCAGATAGATGTTT
<i>BRCA2</i>	PAPZYP	13:32937375	missense	A	G	ACACTGCTGTTCTCCTGTCA	ACAGCATACCACCCATCTGT
<i>CHEK2</i>	PARNEE	22:29121242	missense	G	A	CGCCAGCAACTTACTCATC	GCCCTCTGATGCATGCTTTT
<i>ERCC2</i>	PAPZYP	19:45868346	missense	G	A	GGGCATCAAATTCCTGGGAC	AAGTTGTCCAAAACCCAGC
<i>EZH2</i>	PASEGA	7:148511124	deletion	CAAGT	C	GGGTGCATTACCCAGAGAAA	AGGTGTTGTGAGGGTTGAG
<i>EZH2</i>	PASTXV	7:148515025	deletion	C	---	AAATCCAATCGGCAAAACAC	AGAAGTTTGGCCTGATGTTGA
<i>EZH2</i>	PAVCJZ	7:148544391	deletion	ATG	---	ATTTAGGGAGGCATTTCTGC	TGGCCGCAATTTAGTGTAGA
<i>EZH2</i> (Somatic)	PASEGA	7:148525988- 7:148531881	deletion	5893bp	---	CCACCCTACCTGGCCATAAT	ATTAAGCTCACGGGTGTTGC
<i>FANCD2</i>	PASJYB	3:10076378	splice	G	C	ACACCCTTCCTATCCCAAAGT	TGAAACAAGTGTGCTCTCCC
<i>WRN</i>	PARACS	8:30924657	missense	C	G	GAAGGCTATCTGTGGGTTGTATT	AGCCTGGATTTATTAGCCTTTCA

eTable 6. Gene-based testing for excess burden of P-LP variants vs. PMBB (Excel File)

eTable 7. Gene-based testing for excess burden of P-LP variants vs. gnomAD 2.1 (Excel File)

eTable 8. P-LP variants in genes with excess burden in neuroblastoma.

Gene ^a	Subject Identifier	Gender	COG Risk Group	MYCN status	Variant ^b	AA Change	Variant Type
<i>ALK</i>	PANYGR	Male	High	Not Amplified	c.3749T>C	I1250T	Missense
<i>ALK</i>	PARVLK	Female	High	Not Amplified	c.3824G>A	R1275Q	Missense
<i>ALK</i>	PATDVF	Female	Intermediate	Not Amplified	c.3824G>A	R1275Q	Missense
<i>BARD1</i>	PARSEA	Male	High	Not Amplified	c.448C>T	R150X	Stopgain
<i>BARD1</i>	PATGWT	Male	High	Amplified	c.1921C>T	R641X	Stopgain
<i>BARD1</i>	PAHYWC	Male	High	Amplified	c.334C>T	R112X	Stopgain
<i>BARD1</i>	PATHJZ	Female	Intermediate	Not Amplified	c.860_861del	E287fs	Frameshift
<i>BARD1</i>	PASFDU	Female	High	Not Amplified	c.1690C>T	Q564X	Stopgain
<i>BARD1</i>	PASGEE	Male	High	Not Amplified	c.1677+1G>T	-	Splice
<i>BARD1</i>	PATZRU	Male	High	Not Amplified	c.159-1G>T	-	Splice
<i>BARD1</i>	PASCIX	Male	High	Not Amplified	c.1954_1955insTGAACAGGAA GAAAAGTATG	E652fs	Frameshift
<i>EZH2</i>	PASEGA	Male	High	Not Amplified	c.1774_1777delACTT	T592fs	Frameshift
<i>EZH2</i>	PASTXV	Male	Low	Not Amplified	c.1184delG	G395fs	Frameshift
<i>EZH2</i>	PAPVXS	Male	High	Not Amplified	c.625G>A	D209N	Missense
<i>EZH2</i>	PAVCJZ	Male	High	Not Amplified	c.-1_2delCAT	M1del	Start Lost

eTable 9. Rare germline copy number variants (CNVs) disrupting *BARD1* in neuroblastoma cases

SNP array CNV calls

Sample	CN Change	Estimated Size	Estimated Region	Min Length	Min Region (hg19)	Max Length	Max Region	Probe Median	Probe Count
PAVNLD	CN Loss	168822	chr2:215487324-215656145	161451	chr2:215489130-215650580	176192	chr2:215485519-215661710	-0.39509578	36
PAWNMH	CN Loss	182685	chr2:215549453-215732137	153593	chr2:215562577-215716169	211777	chr2:215536329-215748105	0.436415702	39
PALXTB	CN Loss	70165	chr2:215623659-215693823	49912	chr2:215627397-215677308	90418	chr2:215619921-215710338	0.707099229	16

Validation: WGS (Complete Genomics) Structural Variant Calls

Sample	SV Type	Size	Region (hg19)	Strand	Mate Pair Count	Frequency In Baseline Genome Set
PALXTB	Deletion	61875	chr2:215622570-215684445	+	20	0

Validation: WGS (Complete Genomics) Copy Number Variation Calls

Sample	CNV Type	Size	Region (hg19)	Average Coverage	Relative Coverage	CNV Score (Phred-Scaled)
PALXTB	CN Loss	62000	chr2:215622000-215684000	25	0.5	53

eTable 10. Association of P-LP variants with clinical and tumor characteristics (Full Cohort)

Characteristic	Without P-LP Variants (n=677)		With P-LP variants (n=109)		P-value
	# subjects	% subjects	# subjects	% subjects	
Sex					
Male	384	57%	63	58%	0.9171
Female	293	43%	46	42%	
Age at Diagnosis					
< 18 months	206	30%	36	33%	0.5780
> 18 months	471	70%	73	67%	
COG Risk Group					
Low	91	13%	12	11%	0.6494
Intermediate	100	15%	19	17%	
High	486	72%	78	72%	
INRG Stage					
Stage L1	77	16%	8	12%	0.6157
Stage L2	72	15%	10	15%	
Stage MS	39	8%	3	5%	
Stage M	295	61%	44	68%	
INSS Stage					
Stage 1	34	5%	4	4%	0.2187
Stage 2a	21	3%	3	3%	
Stage 2b	35	5%	1	1%	
Stage3	83	12%	10	9%	
Stage 4	460	68%	86	79%	
Stage 4s	44	6%	5	5%	
MYCN status					
Amplified	201	30%	23	21%	0.0672
Not amplified	467	70%	85	79%	
Histologic Classification					
Favorable	180	27%	31	28%	0.5491
Unfavorable	455	67%	67	61%	
unknown	42	6%	11	10%	
Degree of Differentiation					
Differentiated	30	5%	5	5%	0.8023
Undifferentiated or poorly differentiated	572	95%	89	95%	
Mitosis Karyorrhexis Index					
Low	228	39%	35	39%	0.2276
Intermediate	167	29%	33	37%	
High	184	32%	22	24%	
Ploidy					
Diploid	251	38%	42	39%	0.8307
Hyperdiploid	408	62%	65	61%	
1p LOH					
Yes	193	34%	27	33%	>0.9999
No	377	66%	54	67%	
11q LOH					
Yes	129	23%	29	36%	0.0119*
No	438	77%	51	64%	

eTable 11. Association of P-LP variants with clinical and tumor characteristics (Capture Only)


Characteristic	Without P-LP variants (n=434)		With P-LP variants (n=55)		P-value
	# subjects	% subjects	# subjects	% subjects	
Sex					
Male	234	54%	33	60%	0.4727
Female	200	46%	22	40%	
Age at Diagnosis					
< 18 months	180	41%	30	55%	0.0822
> 18months	254	59%	25	45%	
COG Risk Group					
Low	80	18%	9	16%	0.0962
Intermediate	87	20%	18	33%	
High	267	62%	28	51%	
INRG Stage					
Stage L1	76	20%	8	16%	0.4961
Stage L2	70	18%	10	20%	
Stage MS	26	7%	1	2%	
Stage M	212	55%	31	62%	
INSS Stage					
Stage 1	34	8%	4	7%	0.4352
Stage 2a	21	5%	3	5%	
Stage 2b	34	8%	1	2%	
Stage 3	76	18%	10	18%	
Stage 4	243	56%	36	65%	
Stage 4s	26	6%	1	2%	
MYCN status					
Amplified	128	30%	9	17%	0.0536
Not Amplified	303	70%	45	83%	
Histologic Classification					
Favorable	154	35%	25	45%	0.0954
Unfavorable	264	60%	26	47%	
unknown	16	4%	4	7%	
Degree of Differentiation					
Differentiated	19	5%	3	6%	0.7283
Undifferentiated or poorly differentiated	394	95%	50	94%	
Mitosis Karyorrhexis Index					
Low	164	41%	21	41%	0.1239
Intermediate	111	28%	20	39%	
High	126	31%	10	20%	
Ploidy					
Diploid	151	36%	18	33%	0.7645
Hyperdiploid	270	64%	36	67%	
1p LOH					
Yes	142	33%	19	35%	0.7624
No	284	67%	35	65%	
11q LOH					
Yes	79	19%	17	31%	0.0309*
No	346	81%	37	69%	

eTable 12. Cox proportional hazards regression model results.


Variable¹	Coefficient (95% Confidence Interval)	P-value	Hazard Ratio (95% Confidence Interval)
P-LP Variant	0.3677 (0.0648-0.6706)	0.0174	1.4444 (1.0699-1.9554)
Age at Diagnosis	0.0000 (-0.0001-1.0001)	0.9251	1.0000 (0.9999-1.0001)
Stage 4	1.3102 (0.7826-1.8378)	< 0.0001	3.7069 (2.1871-6.2825)
MYCN amplification	0.2610 (0.0021-0.5199)	0.0481	1.2982 (1.0021-1.6818)
Risk Group	1.0101 (0.5363-1.4839)	< 0.0001	2.7459 (1.7097-4.4100)

¹ Model based on neuroblastoma patients with data on all variables (n=774).


III. SUPPLEMENTARY FIGURES




eFigure 1. Flow diagram of automated pathogenicity assessment for germline variants.
Order of flow indicated by labeled arrows.




eFigure 2. Ancestry of neuroblastoma cohort inferred from principal component analysis. Matched germline Illumina SNP array data were utilized to infer ancestry using principal component analysis of pruned SNPs together with the data from 1000 Genomes.



eFigure 3. *BARD1* germline variants validated by Sanger sequencing. **A.** Lollipop figure depicting pathogenic germline variants in neuroblastoma cases. **B.** Sanger validation of pathogenic germline variants in neuroblastoma. See **eTable 5** for primers used for Sanger sequencing. Variant annotations with respect to ENST00000260947.



eFigure 4. *EZH2* P/LP germline and somatic variants validated by Sanger sequencing. A. Lollipop figure depicting pathogenic germline and somatic variants in neuroblastoma cases. **B.** Sanger validation of pathogenic germline and somatic variants in neuroblastoma patients PAVCJZ, PASTXV, and PASEGA. **C.** Sanger validation of *EZH2* somatic deletion in PASEGA. See **eTable 5** for primers used. Variant annotations with respect to ENST00000320356.



eFigure 5. Ancestry of PMBB cohort inferred from principal component analysis.

IV. BANNER AUTHOR LISTS AND CONTRIBUTIONS

Penn Medicine BioBank Banner Author List and Contribution Statements

PMBB Leadership Team

Daniel J. Rader, M.D., Marylyn D. Ritchie, Ph.D., Michael D. Feldman M.D.

Contribution: All authors contributed to securing funding, study design and oversight. All authors reviewed the final version of the manuscript.

Patient Recruitment and Regulatory Oversight

JoEllen Weaver, Afiya Poindexter, Ashlei Brock, Khadijah Hu-Sain, Yi-An Ko

Contributions: JW manage patient recruitment and regulatory oversight of study. AP, AB, KH, YK recruitment and enrollment of study participants.

Lab Operations

JoEllen Weaver, Meghan Livingstone, Fred Vadivieso, Ashley Kloter, Stephanie DerOhannessian, Teo Tran, Linda Morrel, Ned Haubein, Joseph Dunn

Contribution: JW, ML, FV, SD oversight of lab operations. ML, FV, AK, SD, TT, LM perform sample processing. NH, JD are responsible for sample tracking and the laboratory information management system.

Clinical Informatics

Anurag Verma, Ph.D., Colleen Morse, M.S., Marjorie Risman, M.S., Renae Judy, B.S.

Contribution: All authors contributed to the development and validation of clinical phenotypes used to identify study subjects and (when applicable) controls.

Genome Informatics

Anurag Verma Ph.D., Shefali S. Verma, Ph.D., Yuki Bradford, M.S., Scott Dudek, M.S., Theodore Drivas, M.D., PH.D.

Contribution: A.V., S.S.V. are responsible for the analysis design and infrastructure needed quality control genotype and exome data. Y.B. performed the analysis. T.D. and A.V. provide variant and gene annotations and their functional interpretation of variants.

Regeneron Genetics Center Banner Author List and Contribution Statements

RGC Management and Leadership Team

Goncalo Abecasis, Aris Baras, Michael Cantor, Giovanni Coppola, Andrew Deubler, Aris Economides, Katia Karalis, Luca A. Lotta, John D. Overton, Jeffrey G. Reid, Katherine Siminovitch & Alan Shuldiner

Sequencing and Lab Operations

Christina Beechert, Caitlin Forsythe, Erin D. Fuller, Zhenhua Gu, Michael Lattari, Alexander Lopez, John D. Overton, Maria Sotiopoulos Padilla, Manasi Pradhan, Kia Manoochehri, Thomas D. Schleicher, Louis Widom, Sarah E. Wolf & Ricardo H. Ulloa

Clinical Informatics

Amelia Averitt, Nilanjana Banerjee, Michael Cantor, Dadong Li, Sameer Malhotra, Deepika Sharma & Jeffrey C. Staples

Genome Informatics

Xiaodong Bai, Suganthi Balasubramanian, Suying Bao, Boris Boutkov, Siying Chen, Gisu Eom, Lukas Habegger, Alicia Hawes, Shareef Khalid, Olga Krasheninina, Rouel Lanche, Adam J. Mansfield, Evan K. Maxwell, George Mitra, Mona Nafde, Sean O'Keeffe, Max Orelus, Razvan Panea, Tommy Polanco, Ayesha Rasool, Jeffrey G. Reid, William Salerno, Jeffrey C. Staples, Kathie Sun & Jiwen Xin

Analytical Genomics and Data Science

Goncalo Abecasis, Joshua Backman, Amy Damas, Lee Dobbyn, Manuel Allen Revez Ferreira, Arkopravo Ghosh, Christopher Gillies, Lauren Gurski, Eric Jorgenson, Hyun Min Kang, Michael Kessler, Jack Kosmicki, Alexander Li, Nan Lin, Daren Liu, Adam Locke, Jonathan Marchini, Anthony Marcketta, Joelle Mbatchou, Arden Moscati, Charles Paulding, Carlo Sidore, Eli Stahl, Kyoko Watanabe, Bin Ye, Blair Zhang & Andrey Ziyatdinov

Research Program Management & Strategic Initiatives

Marcus B. Jones, Jason Mighty & Lyndon J. Mitnaul

V. SUPPLEMENTARY REFERENCES

1. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. *Nat Genet.* 2013.
2. Park J, Levin MG, Haggerty CM, et al. A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes. *Genet Med.* 2020;22(1):102-111.
3. Wang L, Desai H, Verma SS, et al. Performance of polygenic risk scores for cancer prediction in a racially diverse academic biobank. *Genet Med.* 2022;24(3):601-609.
4. McDaniel LD, Conkrite KL, Chang X, et al. Common variants upstream of MLF1 at 3q25 and within CPZ at 4p16 associated with neuroblastoma. *PLoS Genet.* 2017;13(5):e1006787.
5. Molenaar JJ, Koster J, Zwijnenburg DA, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. *Nature.* 2012;483(7391):589-593.
6. Brohl AS, Patidar R, Turner CE, et al. Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. *Genet Med.* 2017;19(8):955-958.
7. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics.* 2009;25(14):1754-1760.
8. Cingolani P, Platts A, Wang le L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly (Austin).* 2012;6(2):80-92.
9. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* 2010;38(16):e164.
10. Xiang J, Peng J, Baxter S, Peng Z. AutoPVS1: An automatic classification tool for PVS1 interpretation of null variants. *Hum Mutat.* 2020;41(9):1488-1498.
11. Egolf LE, Vaksman Z, Lopez G, et al. Germline 16p11.2 Microdeletion Predisposes to Neuroblastoma. *American journal of human genetics.* 2019;105(3):658-668.
12. Brady SW, Liu Y, Ma X, et al. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. *Nat Commun.* 2020;11(1):5183.